Ergoteles’s Quince Therapeutics QNCX Stock Holding History

Ergoteles’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-196	Closed	-$25K	–	1675
2022 Q4	$25K	Buy	+196	New	+$32.8K	﹤0.01%	1337
2022 Q3	–	Sell	-490	Closed	-$218K	–	1900
2022 Q2	$218K	Buy	+490	New	+$346K	0.01%	1276

Other funds holding QNCX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Ergoteles's QNCX Position: Q1 2023 in Review

Ergoteles sold out of Quince Therapeutics (QNCX) in Q1 2023, closing a stake of 196 shares — an estimated $25K sold.

Ergoteles first reported a position in QNCX in Q2 2022 and held it in 2 quarters. The position peaked at $218K in Q2 2022. 42 funds tracked by Wall St. Rank hold QNCX as of Q1 2023.

Ergoteles reported no remaining Quince Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 196 Quince Therapeutics shares in Q1 2023, an estimated $25K.
Ergoteles first reported a position in Quince Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Quince Therapeutics position peaked at $218K in Q2 2022.
42 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.